Loading…
SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients
Mone, Pasquale, Varzideh, Fahimeh, Jankauskas, Stanislovas S., Pansini, Antonella, Lombardi, Angela, Frullone, Salvatore, Santulli, Gaetano
Published in Hypertension (Dallas, Tex. 1979) (01.08.2022)
Published in Hypertension (Dallas, Tex. 1979) (01.08.2022)
Get full text
Journal Article
Loading…
Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial
Hammad, Hany, Shaaban, Asmaa, Philips, Mariana Victor, Fayed, Ahmed, Abdelaziz, Tarek Samy
Published in International urology and nephrology (01.09.2023)
Published in International urology and nephrology (01.09.2023)
Get full text
Journal Article
Loading…
Predictors of efficacy of Sodium‐GLucose Transporter‐2 inhibitors and Glucagon‐Like Peptide 1 receptor agonists: A retrospective cohort study
Scoccimarro, Daniele, Cipani, Giacomo, Dicembrini, Ilaria, Mannucci, Edoardo
Published in Diabetes/metabolism research and reviews (01.02.2024)
Published in Diabetes/metabolism research and reviews (01.02.2024)
Get full text
Journal Article
Loading…
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
Kasichayanula, S, Liu, X, Shyu, W.C, Zhang, W, Pfister, M, Griffen, S.C, Li, T, LaCreta, F.P, Boulton, D.W
Published in Diabetes, obesity & metabolism (2011)
Published in Diabetes, obesity & metabolism (2011)
Get full text
Journal Article
Loading…
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
Wang, Xiaoxin X, Levi, Jonathan, Luo, Yuhuan, Myakala, Komuraiah, Herman-Edelstein, Michal, Qiu, Liru, Wang, Dong, Peng, Yingqiong, Grenz, Almut, Lucia, Scott, Dobrinskikh, Evgenia, D'Agati, Vivette D, Koepsell, Hermann, Kopp, Jeffrey B, Rosenberg, Avi Z, Levi, Moshe
Published in The Journal of biological chemistry (31.03.2017)
Published in The Journal of biological chemistry (31.03.2017)
Get full text
Journal Article
Loading…
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
Wiviott, Stephen D., Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A., McGuire, Darren K., Wilding, John PH, Gause-Nilsson, Ingrid AM, Langkilde, Anna Maria, Johansson, Peter A., Sabatine, Marc S.
Published in The American heart journal (01.06.2018)
Published in The American heart journal (01.06.2018)
Get full text
Journal Article
Loading…
Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
Wilcox, Christopher S., Shen, Wen, Boulton, David W., Leslie, Bruce R., Griffen, Steven C.
Published in Journal of the American Heart Association (20.02.2018)
Published in Journal of the American Heart Association (20.02.2018)
Get full text
Journal Article
Loading…
Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology
Maurer, Tristan S., Ghosh, Avijit, Haddish-Berhane, Nahor, Sawant-Basak, Aarti, Boustany-Kari, Carine M., She, Li, Leininger, Michael T., Zhu, Tong, Tugnait, Meera, Yang, Xin, Kimoto, Emi, Mascitti, Vincent, Robinson, Ralph P.
Published in The AAPS journal (01.12.2011)
Published in The AAPS journal (01.12.2011)
Get full text
Journal Article
Loading…
Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
Mudaliar, Sunder, Armstrong, Debra A., Mavian, Annie A., O’Connor-Semmes, Robin, Mydlow, Patricia K., Ye, June, Hussey, Elizabeth K., Nunez, Derek J., Henry, Robert R., Dobbins, Robert L.
Published in Diabetes care (01.11.2012)
Published in Diabetes care (01.11.2012)
Get full text
Journal Article
Loading…
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Yale, J.-F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., Meininger, G.
Published in Diabetes, obesity & metabolism (01.05.2013)
Published in Diabetes, obesity & metabolism (01.05.2013)
Get full text
Journal Article
Loading…
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
Tomita, Issei, Kume, Shinji, Sugahara, Sho, Osawa, Norihisa, Yamahara, Kosuke, Yasuda-Yamahara, Mako, Takeda, Naoko, Chin-Kanasaki, Masami, Kaneko, Tatsuroh, Mayoux, Eric, Mark, Michael, Yanagita, Motoko, Ogita, Hisakazu, Araki, Shin-ichi, Maegawa, Hiroshi
Published in Cell metabolism (01.09.2020)
Published in Cell metabolism (01.09.2020)
Get full text
Journal Article
Loading…
Loading…
Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ferrannini, Ele, Baldi, Simona, Frascerra, Silvia, Astiarraga, Brenno, Heise, Tim, Bizzotto, Roberto, Mari, Andrea, Pieber, Thomas R., Muscelli, Elza
Published in Diabetes (New York, N.Y.) (01.05.2016)
Published in Diabetes (New York, N.Y.) (01.05.2016)
Get full text
Journal Article
Loading…
The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i
Cianciolo, Giuseppe, De Pascalis, Antonio, Gasperoni, Lorenzo, Tondolo, Francesco, Zappulo, Fulvia, Capelli, Irene, Cappuccilli, Maria, La Manna, Gaetano
Published in Molecules (Basel, Switzerland) (15.06.2020)
Published in Molecules (Basel, Switzerland) (15.06.2020)
Get full text
Journal Article
Loading…
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
Dharmalingam, Mala, Aravind, S. R., Thacker, Hemant, Paramesh, S., Mohan, Brij, Chawla, Manoj, Asirvatham, Arthur, Goyal, Ramesh, Shembalkar, Jayashri, Balamurugan, R., Kadam, Pradnya, Alva, Hansraj, Kodgule, Rahul, Tandon, Monika, Vaidyanathan, Sivakumar, Pendse, Amol, Gaikwad, Rajesh, Katare, Sagar, Suryawanshi, Sachin, Barkate, Hanmant
Published in Drugs (New York, N.Y.) (01.04.2020)
Published in Drugs (New York, N.Y.) (01.04.2020)
Get full text
Journal Article
Loading…
SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice
Soares, Rogerio N., Ramirez-Perez, Francisco I., Cabral-Amador, Francisco J., Morales-Quinones, Mariana, Foote, Christopher A., Ghiarone, Thaysa, Sharma, Neekun, Power, Gavin, Smith, James A., Rector, R. Scott, Martinez-Lemus, Luis A., Padilla, Jaume, Manrique-Acevedo, Camila
Published in GeroScience (01.06.2022)
Published in GeroScience (01.06.2022)
Get full text
Journal Article
Loading…
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
Kapur, Anita, O’Connor-Semmes, Robin, Hussey, Elizabeth K, Dobbins, Robert L, Tao, Wenli, Hompesch, Marcus, Smith, Glenn A, Polli, Joseph W, James Jr, Charles D, Mikoshiba, Imao, Nunez, Derek J
Published in BMC pharmacology & toxicology (13.05.2013)
Published in BMC pharmacology & toxicology (13.05.2013)
Get full text
Journal Article
Loading…
Loading…
Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
Polidori, David, Iijima, Hiroaki, Goda, Maki, Maruyama, Nobuko, Inagaki, Nobuya, Crawford, Peter A.
Published in Diabetes, obesity & metabolism (01.05.2018)
Published in Diabetes, obesity & metabolism (01.05.2018)
Get full text
Journal Article
Loading…
Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Proline Henagliflozin in Chinese Subjects with Varying Degrees of Liver Dysfunction
Ding, Likun, Yang, Lin, Ren, Danjun, Gao, Xiaohua, Zhang, Juanli, Liu, Meiyou, Sun, Li, Diao, Qingbo, Feng, Sheng, Wen, Aidong, Wang, Jingwen
Published in Journal of clinical pharmacology (01.08.2024)
Published in Journal of clinical pharmacology (01.08.2024)
Get more information
Journal Article